PLA2R1 and membranous glomerulonephritis: Beck et al. first reported M-type phospholipase A2 receptor (PLA2R) as the major membranous nephropathy target antigen, and testing of 70–80% of patients with primary MN for serum anti-PLA2R antibodies was positive3.